Emerging drug delivery systems with traditional routes - A roadmap to chronic inflammatory diseases

Kiyoon Min; Abhishek Sahu; Sae Hyun Jeon; Giyoong Tae

doi:10.1016/j.addr.2023.115119

Emerging drug delivery systems with traditional routes - A roadmap to chronic inflammatory diseases

Adv Drug Deliv Rev. 2023 Dec:203:115119. doi: 10.1016/j.addr.2023.115119. Epub 2023 Oct 28.

Authors

Kiyoon Min¹, Abhishek Sahu², Sae Hyun Jeon¹, Giyoong Tae³

Affiliations

¹ School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.
² Department of Biotechnology, National Institute of Pharmaceutical Education & Research (NIPER), Hajipur, 844102, India.
³ School of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea. Electronic address: gytae@gist.ac.kr.

PMID: 37898338
DOI: 10.1016/j.addr.2023.115119

Abstract

Inflammation is prevalent and inevitable in daily life but can generally be accommodated by the immune systems. However, incapable self-healing and persistent inflammation can progress to chronic inflammation, leading to prevalent or fatal chronic diseases. This review comprehensively covers the topic of emerging drug delivery systems (DDSs) for the treatment of chronic inflammatory diseases (CIDs). First, we introduce the basic biology of the chronic inflammatory process and provide an overview of the main CIDs of the major organs. Next, up-to-date information on various DDSs and the associated strategies for ensuring targeted delivery and stimuli-responsiveness applied to CIDs are discussed extensively. The implementation of traditional routes of drug administration to maximize their therapeutic effects against CIDs is then summarized. Finally, perspectives on future DDSs against CIDs are presented.

Keywords: Administration route; Chronic inflammatory disease; Drug delivery systems; Inflammation; Stimuli-responsive; Targeting.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Chronic Disease
Drug Delivery Systems*
Humans
Inflammation* / drug therapy